Chlorothiazide Oral Suspension
Brand names: Diuril
Category: Cardiovascular
FDA status: To Be Discontinued · Last FDA update: Feb 10, 2026 · First posted: Feb 10, 2026 · 1 manufacturers, 1 listed presentations
As of Feb 10, 2026, the FDA lists Chlorothiazide Oral Suspension as being discontinued. Of 1 manufacturer presentations, 1 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Diuril, Oral Suspension, 250 mg/5mL (NDC 65649-311-12) NDC 65649-311-12 |
Salix Pharmaceuticals, a division of Bausch Health US, LLC | Not specified | - |
Related medications in shortage
Other Cardiovascular medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Chlorothiazide Oral Suspension (FDA data as of Feb 10, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Chlorothiazide Oral Suspension. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/chlorothiazide-oral-suspension.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).